dacarbazine has been researched along with mibefradil in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Bigner, DD; Friedman, HS; Gray, LA; Keir, ST; Reardon, DA | 1 |
Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X | 1 |
1 trial(s) available for dacarbazine and mibefradil
Article | Year |
---|---|
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Calcium Channels, T-Type; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Mibefradil; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Young Adult | 2017 |
4 other study(ies) available for dacarbazine and mibefradil
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; Dacarbazine; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Glioblastoma; Humans; Kaplan-Meier Estimate; Mibefradil; Mice; Neoplasm Transplantation; Skin Neoplasms; Temozolomide; Time Factors; Xenograft Model Antitumor Assays | 2013 |